Online inquiry

IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3813MR)

This product GTTS-WQ3813MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets NCAM1 gene. The antibody can be applied in Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000615.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684
UniProt ID P13591
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3813MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2326MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ3983MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ7263MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ9158MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ7941MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ2547MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ14437MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ3907MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BCD-135
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW